Regenxbio to File a BLA Using the Accelerated Approval Pathway for RGX-121 for the Hunter Syndrome

Regenxbio in the NEWS 
Regenxbio (RGNX) announced, on August 3, 2022, its intention to file a Biologics License Application (BLA) in 2024 using the FDA's accelerated approval pathway for RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome.  

The Company has also announced that a pivotal program for RGX-121 is . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.